Cambrian Biopharma Licenses mTOR Analogs to Novartis

PRESS RELEASE — Cambrian Biopharma, a multi-asset longevity biotech, announced a licensing agreement with Novartis to advance novel, selective compounds designed and characterized by Novartis to target the mechanistic target of rapamycin (mTOR) pathway. The licensed assets are structural analogs of the FDA-approved drug rapamycin, which has been shown to prevent or reverse multiple age-related health …

Cambrian Biopharma Licenses mTOR Analogs to Novartis Read More »